| Schedule of information about the Company's single segment |
| | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | Revenue | | $ | 13,475 | | $ | 13,459 | | $ | 24,260 | | $ | 24,156 | Cost of product revenue | | | 2,011 | | | 1,944 | | | 3,340 | | | 3,206 | Research and development (a) | | | | | | | | | | | | | Direct program expenses | | | | | | | | | | | | | AXPAXLI | | | 28,756 | | | 33,158 | | | 71,216 | | | 57,613 | Other clinical and preclinical programs | | | 716 | | | 1,001 | | | 1,475 | | | 2,081 | Unallocated expenses | | | | | | | | | | | | | Personnel costs | | | 13,538 | | | 9,350 | | | 26,514 | | | 18,689 | All other costs | | | 2,081 | | | 2,039 | | | 3,890 | | | 4,925 | Selling and marketing (a) | | | 15,079 | | | 12,477 | | | 29,153 | | | 25,251 | General and administrative (a) | | | 14,416 | | | 8,649 | | | 26,022 | | | 18,301 | Facilities (b) | | | 2,487 | | | 1,777 | | | 4,758 | | | 3,508 | Stock-based compensation | | | 14,649 | | | 9,678 | | | 30,231 | | | 20,134 | Depreciation | | | 1,851 | | | 1,027 | | | 3,111 | | | 2,007 | Interest income | | | 5,449 | | | 3,455 | | | 11,500 | | | 7,282 | Interest expense | | | (2,792) | | | (3,016) | | | (5,569) | | | (6,000) | Other non-operating items | | | 689 | | | (612) | | | 2,144 | | | (1,590) | Net loss | | $ | (78,763) | | $ | (67,814) | | $ | (167,375) | | $ | (131,867) |
| (a) | excluding stock-based compensation, depreciation, and facilities expenses |
| (b) | excluding stock-based compensation and depreciation |
|